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It is now accepted that there are antibody-mediated
diseases of both the peripheral and central nervous
systems. Myasthenia gravis remains the prototype auto-
immune disease of the neuromuscular junction, but sub-
sequent studies have revealed antibodies to other
peripheral and autonomic targets. In the 1990s, antibo-
dies to voltage-gated potassium channel complexes were
identified in acquired neuromyotonia, a condition
caused by peripheral nerve hyperexcitatibility that leads
to muscle fasciulations, muscle cramps and pain.
Somewhat surprisingly, the same antibodies were identi-
fied in relatively acute-onset central nervous system
disorders such as Morvan’s syndrome and limbic ence-
phalitis. It turned out that the potassium channel anti-
bodies were mainly directed at other proteins that are
complexed with the channels in situ, such as LGI1 and
CASPR2. These proteins help localise (CASPR2) and
modify (LGI1) potassium channel function, and the anti-
bodies bind to extracellular epitopes and are pathogenic
in vitro. Tumours can be found in a proportion of each
of these conditions, but the proportion varies from
<10% to around 50%. Thymomas are the most common.
In 2007, antibodies to NMDA receptors (NR1 princi-
pally) were identified and subsequently found quite
commonly in younger patients, often women and small
children, who have a very complicated form of encephalitis
that results in psychiatric and movement disorders. Ovar-
ian teratomas are common in the adult females but rare in
children. Other antibodies have now been discovered,
each one directed at a specific receptor or ion-channel
related associated protein, although so far the associated
diseases are fairly rare. Antibodies to glycine receptors are
associated with a form of stiff person plus, usually termed
progressive encephalomyelitis with rigidity and myoclonus
(PERM), a condition which is well described in the litera-
ture and can be life threatening. Now it is recognised in
more patients with a greater breadth of clinical symptoms.
Each of these diseases shows a very good respond to
immunotherapies such as steroids, plasma exchange, intra-
venous immunoglobulins. If the response is poor, second
line therapies such as rituximab and/or cylclophosphamide
are tried. Some require longer term immunosuppression
with azathioprine or mycophenolate. Altogether there is a
growing field of immunotherapy-responsive neurological
diseases which need to be recognised by the clinicians and
treated appropriately. There are now many neurological
presentations in which the possibility of an autoimmune
disease needs to be considered, and this is beginning to
apply to those that are less clearly “organic”.
Disclosure of interest
None declared.
Published: 17 September 2014
doi:10.1186/1546-0096-12-S1-I29
Cite this article as: Vincent: Autoimmume encephalitis. Pediatric
Rheumatology 2014 12(Suppl 1):I29.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submitNuffield Dept of Clinical Neurosciences, University of Oxford, Oxford, OX3
9DU, UK
Vincent Pediatric Rheumatology 2014, 12(Suppl 1):I29
http://www.ped-rheum.com/content/12/S1/I29
© 2014 Vincent; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
